China’s unscrupulous drug manufacturing practices pose a serious risk to the Americans. The fact is that there are increasingly more American drug manufacturers and biotech companies opting to have the drugs and products manufactured oversees. American drug makers are laying off workers and shutting down manufacturing facilities in favor of moving this part of of their business off shore. Unfortunately the movement of drug manufacturing out of the United States seriously compromises the health and safety of Americans who may trust that the drugs they take are safe. As Americans are increasingly forced to take generic drugs without knowledge of where the drug they take is manufactured, the threat to human life becomes greater. The extent to which quality and standards, such as GMPs are adhered to are much lower in countries such as China. Recently there has been stories coming out of Puerto Rico as well regarding lack of regulatory oversight.
The FDA is unable to regulate and oversee operations as extensively in foreign markets. This is something that should be a concern to all American consumers since most all of us are consumers of medications, if not on a routine basis, at some point or another. The lack of federal regulatory safety oversight and accountability is even more disturbing and potentially life threatening if ones considers that the FDA is having difficulty holding drug manufacturing facilities in the U.S. accountable. Since Bush has been in office, the FDAs ability to hold drug companies accountable for their practices has been limited and largely ineffectual. The FDA has insufficient staffing, resources and political mandate to ensure that drug companies are abiding by GMPs (i.e. – Good Manufacturing Practices) as required by law. The ToyRUs toy recall is nothing compared to the harm posed by drugs coming out of China.
To get a sense of the developments in China relative to drug manufacturing, please read the following article:
From Article, China Sentences Former Drug Official to Death by Kristi Barnes
The hardline approach may be an attempt by the country to demonstrate to the world its seriousness in stamping out the corruption that is reportedly rife throughout the healthcare and pharmaceutical, among other industries, and has been muddying the country’s reputation, causing it to miss out on billions of dollars of foreign investment. The death penalty was slammed on Zheng Xiaoyu by a Beijing court for taking over $850,000 (€632,000) worth of bribes in the form of cash and gifts. Incidently he also received a sentence of seven years’ imprisonment for dereliction of duty. In addition, all Zheng’s personal property was confiscated and he was deprived of his political rights for life, according to media reports. His wife and son are also implicated and are still being investigated, among others who are believed to be involved.Zheng, who reigned as China’s chief drug and food official between 1997 and 2006, does, however, still have the right to appeal.According to the court that convicted him, the death sentence was appropriate, given the huge bribes involved and the great damage inflicted on the country and the public by Zheng’s dereliction of duty, it was reported in Xinhua. The degree of Zheng’s corruption is reportedly extensive. According to the court, he “sought benefits” for eight pharmaceutical companies, including the Hainan Kongliyuan Group from South China’s Hainan Province, by inappropriately approving hundreds of drugs and medical devices during a three-year period between 2001 and 2003, six of which proved to be fake.
Dozens of people have been killed by fake and inferior products in China during Zheng’s tenure. In one high profile case in May 2006, nine people died in China after being injected with a concoction of Armillarisni A that contained a fake and toxic ingredient.
In Panama last year, more than 40 people died after taking cough syrup, antihistamine tablets, and calamine lotion which contained glycerine that was contaminated with diethylene glycol (DEG), a poison used in antifreeze and as a solvent. The glycerin was originally sourced from China. Meanwhile, China is also a source of much of the world’s counterfeit drugs – another acute danger to public safety, not to mention the impact on pharma industry revenues. However, after years of suffering from a bad reputation in the pharmaceutical industry, China is now attempting to reverse the damage. Along with the revenue it has been forgoing, China has realised that without serious change it runs the risk of being usurped by its smaller rival India, and it is desperately trying to clean up its image and attract new international business, and in turn big dollars, into the country. The potential for China’s pharmaceutical market is vast and has been growing rapidly, however, many pharma firms have long been avoiding doing business in the country because of concerns over corruption and the degree of product quality control and regulation, as well as fears of that their intellectual property (IP) cannot be protected. In addition to the investigation related to Zheng, recent actions from within the country are an indication corruption is beginning to be seriously tackled, and drug manufacturers who produce substandard or counterfeit medicines seriously clamped down on. The SFDA has just announced it will send 90 officials to carry out drug safety inspections in 15 provinces across the country over the next two weeks. Last year the SFDA also carried out 35 unannounced inspections of drug manufacturing facilities at the end of September last year and revoked the Good Manufacturing Practice (GMP) certificates of 15 companies and imposed fines, while ordering 13 others to rectify production defects. Commenting on the incident previously, SFDA spokesperson Zhang Jixiang, said that companies should think very seriously and run their business honestly and stick to the law.” He accused local drug authorities of “deficient supervision” and urged them to begin making more unscheduled inspections in order to stamp out the “glaring problems” among China’s drug manufacturers.
If you are concerned about this real health threat and want to take action, I encourage you to visit the website “Public Citizen” http://www.citizen.org/ to find out more and find out how to become an activist for reform. The People’s Pharamacy is also a good source of information about drugs.
We need to be the instrument of change that we want to see in society.
Filed under: health, politics | Tagged: China drug manufacturing, drug safety, lack of FDA oversight | Leave a Comment »